4.4 Africa South of the Sahara: The Virus Followed the Roads

 

Section 4: The Virus Followed the Roads

HIV/AIDS, mobility, power, and the systems that sustain life

Viruses do not read maps, but people build routes.

They build ports, railroads, mining towns, truck stops, labor compounds, hospitals, military camps, and borders. They decide who may travel, who must travel, and who is separated from family for months at a time. They decide where clinics are built, whose illness is discussed honestly, and who can afford to miss a day of work for treatment.

HIV has a biological history. The HIV/AIDS epidemic also has a geography.

HIV, the human immunodeficiency virus, attacks the immune system. AIDS, acquired immunodeficiency syndrome, is the advanced stage of infection that can develop when HIV is untreated. Effective antiretroviral treatment can suppress the virus, protect the immune system, and prevent progression to AIDS.

That distinction matters because the meaning of an HIV diagnosis has changed. In the 1980s and 1990s, it often meant an early death. Today, where testing and treatment are accessible, a person living with HIV can have a long life, relationships, employment, and children born without HIV.

The geography of that transformation is as important as the geography of the epidemic.

A Virus with a History

The primary pandemic form of HIV emerged after a simian immunodeficiency virus crossed from another primate into humans. Such crossings occurred more than once. Most did not produce a worldwide epidemic.

One lineage did.

Genetic and historical research places the early expansion of the pandemic HIV-1 group M lineage in Kinshasa, in what is now the Democratic Republic of the Congo, during the early twentieth century. Expanding colonial transportation networks helped connect the city to other population centers (Faria et al., 2014).

This does not mean a railroad caused AIDS. It means that a rare virus encountered a newly connected human landscape.

Kinshasa was growing rapidly. Riverboats, rail lines, commercial networks, and labor migration brought people together across long distances. Colonial rule reorganized work and settlement. Gender ratios in some cities became highly unequal because male laborers were recruited without their families. Medical services were limited, sexually transmitted infections were frequently untreated, and people circulated among cities, workplaces, and rural homes.

The virus entered this machinery quietly. For decades, no one knew it was there.

The Mine, the Hostel, and the Road Home

The epidemic became especially severe in parts of eastern and southern Africa. No single cultural practice explains this pattern. The more convincing explanation lies in overlapping systems of mobility, labor, inequality, health, and political response.

Colonial mining economies recruited workers from enormous areas. Men traveled to copper mines in Zambia and the Congo, gold mines in South Africa, and industrial centers across the region. In South Africa, apartheid intensified the system. Black workers were housed in crowded, single-sex compounds while their families remained in rural areas or designated homelands.

Workers were not simply moving from one permanent home to another. Many circulated. A man might spend months at a mine, return to a rural household, and later leave again.

The same transportation system that carried minerals toward ports carried workers between cities, compounds, commercial farms, and villages.

Long separations affected sexual relationships. Mining towns and transport corridors developed economies serving overwhelmingly male populations. Untreated sexually transmitted infections increased biological vulnerability. When workers returned home, the virus moved through marriages and long-term partnerships as well as casual relationships.

This is a causal chain, not a moral judgment.

The railroad was built to move wealth out of the ground. The labor compound was built to control workers. The pass system was built to regulate Black movement. None was designed to spread HIV. Together, however, they created a landscape in which a sexually transmitted virus could travel widely.

Colonialism did not invent every inequality or every form of migration. It reorganized them at a continental scale and often made them more coercive.

Power Shapes Exposure

Public discussion of HIV has frequently concentrated on individual behavior: use a condom, remain faithful, get tested, and take medication.

Those actions matter. But the ability to take them is unequally distributed.

A woman who depends economically on a husband or older partner may understand how HIV is transmitted and still be unable to insist on condom use. A migrant worker may avoid testing because a positive result threatens employment or exposes him to stigma. A young person may live far from a clinic or fear being recognized there. LGBTQ people, sex workers, prisoners, and people who use drugs may avoid health services when their identities or activities are criminalized.

Knowledge is not the same thing as power.

Women and girls accounted for approximately 63 percent of new HIV infections in Africa south of the Sahara in 2024. Adolescent girls and young women remain especially vulnerable, reflecting biological risk but also economic dependence, gender-based violence, interrupted education, and relationships marked by unequal power (UNAIDS, 2025a).

This should not become another easy explanation involving “African culture.” Gender inequality exists worldwide. What varies is how it intersects with poverty, labor migration, age differences, access to treatment, legal protections, and public institutions.

Culture is part of the landscape. It is not an explanation that permits us to stop thinking.

An Epidemic That Was Never Uniform

A continental map can make HIV appear to be a single African condition. It is not.

Prevalence has historically been highest across much of southern Africa, while many West African countries have had lower national rates. Individual cities, transportation corridors, border districts, and occupational groups can differ greatly from national averages.

Some countries developed effective treatment and prevention systems early. Others delayed action or struggled through war, debt, limited clinical capacity, and political denial.

Even within one country, two people living only a few kilometers apart may inhabit different medical worlds. One has a nearby clinic, reliable transportation, confidential testing, and uninterrupted medication. The other faces clinic closures, medication shortages, stigma, and the cost of a bus fare.

A national percentage cannot show that distance.

The Public-Health Counteroffensive

The early HIV/AIDS years produced fear, misinformation, discrimination, and enormous loss. They also produced activism.

People living with HIV organized. African doctors, nurses, researchers, community health workers, religious organizations, and advocacy groups fought for testing, affordable medicine, and honest public policy. South Africa’s Treatment Action Campaign became one of the best-known examples, challenging pharmaceutical prices as well as government failures.

The price of antiretroviral drugs fell. Generic medicines expanded access. Governments created national treatment programs. The Global Fund and the U.S. President’s Emergency Plan for AIDS Relief supplied funding, medication, laboratories, training, and health workers.

By September 2024, PEPFAR estimated that programs it supported had saved 26 million lives and were providing antiretroviral treatment to more than 20 million people (PEPFAR, 2024).

The results are visible.

Between 2010 and 2024, annual new HIV infections in eastern and southern Africa fell by approximately 56 percent, from about 1.1 million to 490,000. AIDS-related deaths fell by approximately 59 percent, from about 630,000 to 260,000 (UNAIDS, 2025b).

Those figures represent one of the great public-health achievements of the modern era.

They also represent millions of ordinary acts: taking a pill every day, transporting samples to a laboratory, driving medicine to a rural clinic, counseling a frightened teenager, completing a test, speaking honestly with a partner, and demanding that a government keep its promises.

Treatment Is Prevention

Modern antiretroviral therapy can reduce the amount of HIV in a person’s blood to an undetectable level. A person who maintains an undetectable viral load does not sexually transmit HIV. This principle is summarized as U=U: Undetectable equals Untransmittable (WHO, 2023).

That fact changes the social meaning of treatment.

Medication is not only care for one person. It is prevention for partners and communities. It allows couples with different HIV statuses to maintain sexual relationships without transmission when viral suppression is sustained. Treatment during pregnancy and breastfeeding can reduce vertical transmission to extremely low levels.

Several African countries have reached or surpassed the international 95-95-95 targets: 95 percent of people living with HIV know their status, 95 percent of those diagnosed receive treatment, and 95 percent of those receiving treatment achieve viral suppression.

Botswana, Eswatini, Lesotho, Namibia, Rwanda, Zambia, and Zimbabwe were among the countries meeting those targets by the end of 2024 (UNAIDS, 2025c).

These accomplishments complicate the old image of Africa as a place where medicine simply arrives from somewhere else. African countries are not merely recipients of the HIV response. Several have become global leaders in testing, treatment, community delivery, and prevention of vertical transmission.

Prevention Has Become a Toolbox

There is no single HIV-prevention technology. Effective programs combine methods:

• condoms and sexual-health education;
• accessible and confidential testing;
• antiretroviral treatment and viral suppression;
• pre-exposure prophylaxis, or PrEP;
• post-exposure prophylaxis, or PEP;
• voluntary medical male circumcision;
• prevention of vertical transmission;
• treatment of other sexually transmitted infections;
• harm-reduction services;
• and legal protections that make people less afraid to seek care.

New tools may alter the geography of prevention. In 2025, the World Health Organization recommended injectable lenacapavir, administered twice yearly, as an additional form of PrEP (WHO, 2025).

A twice-yearly injection may be easier for some people than taking a daily pill. But invention does not guarantee access. Cost, licensing, supply chains, clinic capacity, and political commitment determine who actually receives it.

The geography of a medical breakthrough is created after the breakthrough itself.

When Washington Entered the Clinic

On January 20, 2025, the Trump administration ordered a pause in U.S. foreign assistance while programs were reviewed. The decision reached African clinics almost immediately.

PEPFAR-supported staff were told to stop work. Testing and outreach programs were interrupted. Supply chains became uncertain. Some clinics reduced services or closed. Programs serving young people and marginalized populations were especially vulnerable.

Waivers eventually allowed portions of lifesaving HIV treatment to continue, and some activities resumed. But waivers did not prevent widespread service gaps. UNAIDS documented disruptions in South Africa, Kenya, Lesotho, Cameroon, Côte d’Ivoire, Uganda, Mali, and other countries (UNAIDS, 2025d).

This episode should not be reduced to a partisan aside. It reveals the geography of health dependence.

A decision made in Washington can determine whether a clinic in Kenya has testing supplies, whether an outreach worker in South Africa remains employed, or whether a patient in Uganda receives help returning to treatment.

Foreign assistance helped create the public-health counteroffensive that saved millions of lives. Its sudden interruption showed how much of that success rested on financial decisions made outside the countries carrying the heaviest disease burden.

The lesson is not that international assistance was a mistake. Without it, millions more people would have died.

The lesson is that a lifesaving system remains vulnerable when too much of its financing, staffing, and technical infrastructure can be altered by one distant government.

African governments and regional institutions consequently face a difficult task. They must defend continued international cooperation while increasing domestic financing, pharmaceutical production, laboratory capacity, and control over health systems.

Medical sovereignty does not mean isolation. It means that a person’s medication should not vanish because politics changed in another country.

Success Can Be Reversed

The epidemic is no longer the unchecked catastrophe described in many older textbooks. Neither is it over.

Eastern and southern Africa still carry a large portion of the world’s HIV burden. Children, men with low testing rates, adolescent girls, young women, and marginalized populations continue to experience gaps in prevention and treatment. Smaller epidemics in some places have grown even while the larger regional trend has improved.

The funding disruption of 2025 made another truth visible: treatment is not just a pill.

Treatment is the truck that delivers the pill, the laboratory that monitors viral load, the nurse who answers questions, the community worker who finds someone lost to care, the electrical system keeping records available, and the government or donor paying for each link.

Break enough links and the medicine becomes an object sitting in the wrong place.

This brings the chapter’s argument full circle.

Geography helped make the epidemic. Colonial labor systems separated families. Railroads and roads connected distant populations. Inequality influenced whose exposure was greatest. Political choices delayed treatment or accelerated it.

Geography can also help unmake the epidemic.

The road that once carried an infected worker home can carry medicine. The railroad built to move copper toward the coast can connect laboratories and clinics. The community once stigmatized into silence can organize. A government once structured for extraction can build a health system that sustains life.

The virus followed the roads.

So did the response.

Whether that response continues will depend on who controls the roads, pays the workers, purchases the medicine, and refuses to let another person disappear from care.

References

Faria, N. R., Rambaut, A., Suchard, M. A., Baele, G., Bedford, T., Ward, M. J., Tatem, A. J., Sousa, J. D., Arinaminpathy, N., Pépin, J., Posada, D., Peeters, M., Pybus, O. G., & Lemey, P. (2014). The early spread and epidemic ignition of HIV-1 in human populations. Science, 346(6205), 56–61. https://doi.org/10.1126/science.1256739

Fouberg, E. H., & Moseley, W. G. (2017). Understanding world regional geography (2nd ed.). Wiley.

Hunter, M. (2010). Love in the time of AIDS: Inequality, gender, and rights in South Africa. Indiana University Press.

Iliffe, J. (2006). The African AIDS epidemic: A history. James Currey.

Joint United Nations Programme on HIV/AIDS. (2025a). Global HIV & AIDS statistics: Fact sheet. https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf

Joint United Nations Programme on HIV/AIDS. (2025b). Eastern and southern Africa: Regional profile, 2025 Global AIDS Update. https://www.unaids.org/en/resources/documents/2025/2025-global-aids-update-esa

Joint United Nations Programme on HIV/AIDS. (2025c). AIDS, crisis and the power to transform: Global AIDS Update 2025. https://www.unaids.org/en/UNAIDS-global-AIDS-update-2025

Joint United Nations Programme on HIV/AIDS. (2025d). Impact of U.S. funding cuts on the global HIV response. https://www.unaids.org/en/impact-US-funding-cuts

U.S. Department of State. (2024). PEPFAR latest global results factsheet. https://www.state.gov/pepfar-latest-global-results-factsheet-dec-2024

World Health Organization. (2023, July 23). New WHO guidance on HIV viral suppression and scientific updates released at IAS 2023. https://www.who.int/news/item/23-07-2023-new-who-guidance-on-hiv-viral-suppression-and-scientific-updates-released-at-ias-2023

World Health Organization. (2025, July 14). WHO recommends injectable lenacapavir for HIV prevention. https://www.who.int/news/item/14-07-2025-who-recommends-injectable-lenacapavir-for-hiv-prevention